Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Samuel C. Blackman Sells 10,000 Shares

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) insider Samuel C. Blackman sold 10,000 shares of the business’s stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $16.01, for a total value of $160,100.00. Following the completion of the transaction, the insider now owns 1,184,662 shares in the company, valued at approximately $18,966,438.62. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Day One Biopharmaceuticals Stock Up 1.7 %

Shares of NASDAQ:DAWN opened at $15.79 on Thursday. The business has a 50 day moving average price of $15.11 and a 200 day moving average price of $13.52. Day One Biopharmaceuticals, Inc. has a twelve month low of $9.67 and a twelve month high of $17.85. The company has a market cap of $1.38 billion, a price-to-earnings ratio of -6.63 and a beta of -1.48.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its earnings results on Monday, February 26th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.07). Analysts anticipate that Day One Biopharmaceuticals, Inc. will post -2.66 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have commented on the company. The Goldman Sachs Group lowered their target price on Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a research note on Tuesday, February 27th. Piper Sandler reiterated an “overweight” rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a research note on Tuesday. Finally, Oppenheimer reiterated a “market perform” rating on shares of Day One Biopharmaceuticals in a research note on Tuesday, February 27th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $40.60.

Institutional Trading of Day One Biopharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. raised its holdings in Day One Biopharmaceuticals by 130.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,226 shares of the company’s stock valued at $27,000 after acquiring an additional 1,262 shares in the last quarter. Quest Partners LLC acquired a new position in Day One Biopharmaceuticals in the 4th quarter valued at approximately $29,000. Metropolitan Life Insurance Co NY raised its holdings in Day One Biopharmaceuticals by 77.2% in the 2nd quarter. Metropolitan Life Insurance Co NY now owns 2,736 shares of the company’s stock valued at $33,000 after acquiring an additional 1,192 shares in the last quarter. Quintet Private Bank Europe S.A. raised its holdings in Day One Biopharmaceuticals by 43.2% in the 4th quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock valued at $48,000 after acquiring an additional 1,000 shares in the last quarter. Finally, Ameritas Investment Partners Inc. raised its holdings in Day One Biopharmaceuticals by 87.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,066 shares of the company’s stock valued at $49,000 after acquiring an additional 1,895 shares in the last quarter. Institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.